Skip to main navigation Skip to search Skip to main content

First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial

  • Clemens Von Birgelen
  • , Taku Asano
  • , Giovanni Amoroso
  • , Adel Aminian
  • , Salvatore Brugaletta
  • , Mathias Vrolix
  • , Rosana Hernandez-Antolín
  • , Pim Van De Harst
  • , Andres Iñiguez
  • , Luc Janssens
  • , Pieter C. Smits
  • , Joanna J. Wykrzykowska
  • , Vasco Gama Ribeiro
  • , Hélder Pereira
  • , Pedro Canas Da Silva
  • , Jan J. Piek
  • , Yoshinobu Onuma
  • , Patrick W. Serruys
  • , Manel Sabaté
  • Thoraxcentrum Twente
  • University of Amsterdam
  • St. Luke's International Hospital Tokyo
  • Onze Lieve Vrouwe Gasthuis
  • Centre Hospitalier Universitaire de Charleroi
  • Hospital Clínic
  • Oost Limburg Hospital
  • Hospital Universitario Ramón y Cajal
  • University of Groningen
  • University Medical Center Groningen
  • Hospital Alvaro Cunqueiro
  • Imelda Hospital
  • Maasstad Hospital
  • Gaia/Espinho Hospital Centers
  • Hospital Garcia de Orta
  • Santa Maria University Hospital
  • Erasmus MC
  • Cardialysis BV
  • Imperial College London

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

18 Citations (Scopus)

Abstract

Aims: A second iteration of a sirolimus-eluting stent (SES) that has a biodegradable PLGA polymer coating with an electrografting base layer on a thin-strut (80 µm) cobalt-chromium platform (BuMA Supreme; SINOMED, Tianjin, China) has been developed. This first-in-man trial aimed to assess the efficacy and safety of the novel device. Methods and results: This randomised, multicentre, single-blinded, non-inferiority trial compared the BuMA Supreme SES versus a contemporary durable polymer zotarolimus-eluting stent (ZES) in terms of angiographic in-stent late lumen loss (LLL) at nine-month follow-up as the primary endpoint. A total of 170 patients were randomly allocated to treatment with either SES (n=83) or ZES (n=87). At nine-month angiographic follow-up, in-stent LLL was 0.29±0.33 mm in the SES group and 0.14±0.37 mm in the ZES group (pnon-inferiority=0.45). The in-stent percent diameter stenosis and the binary restenosis rate of the two treatment arms were similar (19.2±12.0% vs. 16.1±12.6%, p=0.09, and 3.3% vs. 4.4%, p=1.00, respectively). At 12-month clinical follow-up, there was no difference between treatment arms with regard to the device-oriented composite clinical endpoint (4.9% vs. 5.7%; p=0.72). Conclusions: The PIONEER trial did not meet its primary endpoint in terms of in-stent LLL at nine-month follow-up. However, this result did not translate into any increase in restenosis rate or impairment in 12-month clinical outcomes.

Original languageEnglish
Pages (from-to)2026-2035
Number of pages10
JournalEuroIntervention
Volume13
Issue number17
DOIs
Publication statusPublished - Apr 2018
Externally publishedYes

Keywords

  • Drug-eluting stent
  • QCA
  • Stable angina

Fingerprint

Dive into the research topics of 'First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial'. Together they form a unique fingerprint.

Cite this